J9042 Brentuximab vedotin injection
Also known as: brentuximab vedotin, Adcetris
Intravenous injection of brentuximab vedotin, an anti-CD30 monoclonal antibody linked to a microtubule-disrupting agent.
In Plain Language
targeted chemotherapy antibody; cancer cell-seeking drug
Clinical Context
Used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphomas expressing CD30 on cell surface.
RVU Information
CPT J9042 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9042?
CPT J9042 (Brentuximab vedotin injection) is a J Codes (Drugs) code. Intravenous injection of brentuximab vedotin, an anti-CD30 monoclonal antibody linked to a microtubule-disrupting agent.
How is J9042 administered?
CPT J9042 is administered by a healthcare provider, typically via injection or infusion. Used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphomas expressing CD30 on cell surface. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9042 used?
Used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphomas expressing CD30 on cell surface.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.